Literature DB >> 28224135

Aortic utero-ovarian sentinel nodes and left infrarenal aortic lymph node dissection by ICG supported navigation.

Rainer Kimmig1, Peter Rusch1, Paul Buderath1, Bahriye Aktas1.   

Abstract

•Visualization of paraaortic sentinel compartments in endometrial cancer•Nerve sparing dissection of left paraaortic infrarenal lymph compartment•Educational video may be basis for standardization of paraaortic sentinel node dissection.

Entities:  

Year:  2017        PMID: 28224135      PMCID: PMC5310174          DOI: 10.1016/j.gore.2017.02.003

Source DB:  PubMed          Journal:  Gynecol Oncol Rep        ISSN: 2352-5789


Abstract

Lymphatic spread in endometrial cancer occurs along two major pathways: the uterine vascular mesometrium to the pelvic iliac lymph compartment and via the ovarian mesonephric pathway (infundibulopelvic ligament) to the paraaortic nodes visualized in (Kimmig et al., 2016a, Kimmig et al., 2016b). However, it could be shown that in pelvic negative nodes following pelvic lymphadenectomy and even pelvic sentinel node excision the incidence of positive paraaortics is as low as 1–2% (Abu-Rustum et al., 2009, Kim et al., 2016, Holloway et al., 2016, Zahl Eriksson et al., 2016). Thus, it could be reasonable to omit paraaortic and even pelvic systematic lymphadenectomy in patients with negative sentinels to reduce morbidity (Tschernichovsky et al., 2016). However, in patients with pT1b/G2 and 3 tumors percentage of isolated positive paraaortic nodes may be significantly higher (Kumar et al., 2014): paraaortic sentinel node resection may be useful to identify their risk correctly. In addition, ICG-guided navigation could also support the resection of the complete paraaortic compartment in case of proven positive nodes. In this video, the visualization of the lymphatic paraaortic drainage of the uterine corpus has been achieved by application of 4 × 0.5 ml of a 1.66 mg/ml solution of indocyanine green (ICG Pulsion®) intracorporal into the uterine fundus and midcorporal, right and left. It was injected via an Iowa-trumpet transcervically in about 0.5 cm myometrial depth, each. The video defines the technique of “en bloc” resection of paraaortic nodes together with the connecting ovarian lymph vessels isolated from their attachment to the colonic mesentery and preserving the inferior mesenteric plexus. It will also be basis for identification of paraaortic sentinel nodes in an international multicenter study under consideration (Kimmig et al., unpublished data).
  8 in total

1.  The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes.

Authors:  Nadeem R Abu-Rustum; Jacob D Gomez; Kaled M Alektiar; Robert A Soslow; Martee L Hensley; Mario M Leitao; Ginger J Gardner; Yukio Sonoda; Dennis S Chi; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2009-08-09       Impact factor: 5.482

2.  Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer.

Authors:  Sanjeev Kumar; Karl C Podratz; Jamie N Bakkum-Gamez; Sean C Dowdy; Amy L Weaver; Michaela E McGree; William A Cliby; Gary L Keeney; Gillian Thomas; Andrea Mariani
Journal:  Gynecol Oncol       Date:  2013-10-09       Impact factor: 5.482

Review 3.  The Role of Lymphadenectomy Versus Sentinel Lymph Node Biopsy in Early-stage Endometrial Cancer: A Review of the Literature.

Authors:  Roi Tschernichovsky; Elisabeth J Diver; John O Schorge; Annekathryn Goodman
Journal:  Am J Clin Oncol       Date:  2016-10       Impact factor: 2.339

4.  Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis.

Authors:  Robert W Holloway; Sarika Gupta; Nicole M Stavitzski; Xiang Zhu; Erica L Takimoto; Ajit Gubbi; Glenn E Bigsby; Lorna A Brudie; James E Kendrick; Sarfraz Ahmad
Journal:  Gynecol Oncol       Date:  2016-03-02       Impact factor: 5.482

5.  Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion.

Authors:  Ane Gerda Zahl Eriksson; Jen Ducie; Narisha Ali; Michaela E McGree; Amy L Weaver; Giorgio Bogani; William A Cliby; Sean C Dowdy; Jamie N Bakkum-Gamez; Nadeem R Abu-Rustum; Andrea Mariani; Mario M Leitao
Journal:  Gynecol Oncol       Date:  2015-12-31       Impact factor: 5.482

6.  Survival impact based on the thoroughness of pelvic lymphadenectomy in intermediate- or high-risk groups of endometrioid-type endometrial cancer: A multi-center retrospective cohort analysis.

Authors:  Tae Hun Kim; Hee Seung Kim; Tae-Joong Kim; Suk-Joon Chang; Dae-Yeon Kim; Sang-Young Ryu; Byoung-Gie Kim; Young-Tak Kim; Duk-Soo Bae; Hee-Sug Ryu; Joo-Hyun Nam
Journal:  Gynecol Oncol       Date:  2016-04-08       Impact factor: 5.482

7.  Intraoperative navigation in robotically assisted compartmental surgery of uterine cancer by visualisation of embryologically derived lymphatic networks with indocyanine-green (ICG).

Authors:  Rainer Kimmig; Bahriye Aktas; Paul Buderath; Peter Rusch; Martin Heubner
Journal:  J Surg Oncol       Date:  2016-01-21       Impact factor: 3.454

8.  Robotically assisted peritoneal mesometrial resection (PMMR) in endometrial cancer supported by ICG labeling of the compartmental lymphatic system.

Authors:  Rainer Kimmig; Bahriye Aktas; Paul Buderath; Martin Heubner
Journal:  Gynecol Oncol Rep       Date:  2016-03-19
  8 in total
  1 in total

Review 1.  IGCS Intraoperative Technology Taskforce. Update on near infrared imaging technology: beyond white light and the naked eye, indocyanine green and near infrared technology in the treatment of gynecologic cancers.

Authors:  Nadeem R Abu-Rustum; Roberto Angioli; Arthur E Bailey; Vance Broach; Alessandro Buda; Michelle R Coriddi; Joseph H Dayan; Michael Frumovitz; Yong Man Kim; Rainer Kimmig; Mario M Leitao; Mustafa Zelal Muallem; Matt McKittrick; Babak Mehrara; Roberto Montera; Lea A Moukarzel; Raj Naik; Silvana Pedra Nobre; Marie Plante; Francesco Plotti; Oliver Zivanovic
Journal:  Int J Gynecol Cancer       Date:  2020-03-30       Impact factor: 3.437

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.